Opioids and the gastrointestinal tract - a case of narcotic bowel syndrome and literature review

Journal of Neurogastroenterology and Motility

Volumn 19, Issue 1, 2013, Pages 94-98

  Farmer, Adam D ^a,b   Ferdinand, Ella ^b   Aziz, Qasim ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

Analgesics; Gastrointestinal tract; Narcotics; Opioid

Indexed keywords

CLONIDINE; DULOXETINE; FENTANYL; LORAZEPAM; METHADONE; MORPHINE; MORPHINE SULFATE; TRAMADOL;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; CHRONIC PAIN; COLON RESECTION; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DETOXIFICATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INFORMED CONSENT; INTRACTABLE PAIN; NARCOTIC BOWEL SYNDROME; NARCOTIC DEPENDENCE; PRESCRIPTION;

EID: 84876739092     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2013.19.1.94     Document Type: Article

References (16)

1. Davis MP. The opioid bowel syndrome: a review of pathophysiology and treatment. J Opioid Manag 2005;1:153-161.
2. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39.
3. Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125:172-179.
4. Sandgren JE, McPhee MS, Greenberger NJ. Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. Ann Intern Med 1984;101:331-334.
5. Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126-1139.
6. Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000;84:121-131.
7. Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD006140.
8. Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000;20:7074-7079.
9. Bian D, Ossipov MH, Ibrahim M, et al. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. Brain Res 1999;831:55-63.
10. Nichols ML, Lopez Y, Ossipov MH, Bian D, Porreca F. Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy. Pain 1997;69:317-322.
11. Milligan ED, Sloane EM, Watkins LR. Glia in pathological pain: a role for fractalkine. J Neuroimmunol 2008;198:113-120.
12. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 2005;28: 661-669.
13. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2007;(4):CD003971.
14. Hakim A, Keer R, Grahame R. Hypermobility, fibromyalgia and chronic pain. London: Churchill Livingstone 2010.
15. Di Palma JA, Cleveland MV, McGowan J, Herrera JL. An open-label study of chronic polyethylene glycol laxative use in chronic constipation. Aliment Pharmacol Ther 2007;25:703-708.
16. Gibson PR, Morrison G. Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study. Intern Med 2012;42:907-912.